The Supreme Court just agreed to hear Emulex Corp. v. Varjabedian, which presents something of a puzzle for merger law and policy.
In brief, Emulex agreed to be acquired by Avago in a friendly tender offer under DGCL 251(h). When Emulex issued its Schedule 14D-9 recommending that shareholders tender their shares, it failed to mention that its bankers found the premium was on the low side as compared to similar deals. The plaintiffs sued, alleging that the omission rendered Emulex’s recommendations misleading in violation of Exchange Act Section 14(e), which prohibits false statements in connection with tender offers. In the courts below, the defendants argued, among other things, that the plaintiffs failed to plead that any misleading statements were made with scienter. On appeal, the Ninth Circuit broke with other circuits and held that scienter is not a required element of a Section 14(e) violation.
When the defendants petitioned for certiorari, here’s how they phrased the Question Presented:
Whether the Ninth Circuit correctly held, in express disagreement with five other courts of appeals, that Section 14(e) of the Securities Exchange Act of 1934 supports an inferred private right of action based on a negligent misstatement or omission made
